SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rispoval 2 / BRSV + Pi3 lyophilisate and solvent for suspension for injection for cattle

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 4 ml dose contains:

Active substances:

Lyophilisate
Bovine parainfluenza virus 3 (Pi3V), strain RLB 103, live $10^{5.0}$ - $10^{8.6}$ $CCID_{50}$.
Bovine respiratory syncytial virus (BRSV), strain 375, live $10^{5.0}$ - $10^{7.2}$ $CCID_{50}$.

$CCID_{50}$ = Cell Culture Infectious Dose 50%.

Adjuvant:

Aluminium hydroxide gel 0.8 ml (equivalent to 24.36 mg of aluminium hydroxide).

Excipients:

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Lyophilisate: slightly whitish to yellowish freeze-dried pellet.
Solvent: pinkish to orange-brown turbid liquid, which might contain loose sediment.
On shaking well, the sediment is easily resuspended.

4. CLINICAL PARTICULARS

4.1 Target species

Cattle.

4.2 Indications for use, specifying the target species

For vaccination with Rispoval 2 only:
Active immunisation of cattle from 12 weeks of age to:
- reduce virus excretion caused by bovine Pi3V and
- reduce virus excretion caused by BRSV infection.

Onset of immunity: 3 weeks after the basic vaccination scheme.

Duration of immunity: 6 months after the basic vaccination scheme for BRSV. Duration of immunity has not been established for bovine Pi3V.

For active immunisation with Rispoval RS+Pi3 IntraNasal* as basic vaccination and Rispoval 2 as booster vaccination from 13 weeks of age to:
- reduce the virus excretion caused by bovine Pi3V and BRSV infection and
- reduce the clinical signs (cough, depression, dyspnea, increased respiratory rate, elevated rectal temperature) associated with BRSV infection.

Onset of Immunity: 3 weeks after the booster vaccination.
Duration of Immunity: 6 months for BRSV and 3 months for Pi3V after the booster vaccination.

* Where this veterinary medicinal product is authorised.

4.3 Contraindications

None.

4.4 Special warnings for each target species

Vaccinate healthy animals only.

4.5 Special precautions for use

Special precautions for use in animals
Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment
Not applicable.

Other precautions
Not applicable.

4.6 Adverse reactions (frequency and seriousness)

Cattle:

Very common (>1 animal / 10 animals treated):	Hyperthermia[1] Injection site inflammation[2]
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction (e.g. anaphylactic-type reaction)[3]

[1]Transient and mild; can last for 2 days.

[2]Transient and minor; up to 0.5 cm which disappears within 15 days.
[3]In case of anaphylactic reaction, symptomatic treatment should be provided.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

4.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The safety and efficacy of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amount(s) to be administered and administration route

Dose: 4 ml.

Route: intramuscular use.

Reconstitution of the vaccine:

Reconstitute the vaccine by adding the solvent to the vial containing the lyophilisate.

When the lyophilisate and solvent are filled in equally sized vials, inject the entire solvent into the vial containing the lyophilisate.

When the lyophilisate is filled in a smaller vial size than the solvent, the reconstitution of the vaccine is carried out in 2 steps:

1. Inject 10 ml of the solvent on the lyophilised plug in the vial containing the lyophilisate.
2. Shake well and extract the reconstituted lyophilised fraction from the vial and mix with the remaining solvent in the liquid fraction vial.

Shake well before use.

Reconstituted product: pink-orange turbid suspension with loose sediment.

Vaccination scheme:
For vaccination with Rispoval 2 only:
Basic vaccination: two doses 3-4 weeks apart from 12 weeks of age.
Re-vaccination: if continued protection against BRSV is required, then animals should be revaccinated with two doses after 6 months. The duration of immunity of the Pi3V component is not known.

For use as a booster vaccination after basic vaccination with Rispoval RS+Pi3 IntraNasal*:
A single dose of Rispoval 2 three months after the basic vaccination with Rispoval RS+Pi3 IntraNasal*.
If continued protection against BRSV is required, then animals should be revaccinated with a single dose after 6 months. If continued protection against Pi3V is required, then animals should be revaccinated with a single dose after 3 months.

* Where this veterinary medicinal product is authorised.

Animals should preferably be vaccinated at least 3 weeks before a period of stress or high infection risk such as re-grouping or transport of animals, or the start of autumn season.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Reactions after administration of an overdose of vaccine are not different from those after the single dose.

4.11 Withdrawal period(s)

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: immunologicals for bovidae, cattle, live viral vaccines, bovine Respiratory syncytial virus + bovine Parainfluenza virus.

ATCvet code: QI02AD07

To stimulate an active immunity against Pi3V and BRSV.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lyophilisate:
Lactose Monohydrate
Potassium hydrogen phosphate
Dipotassium phosphate
Monopotassium L-glutamate
Water, purified
Gelatin
Casein hydrolysate solution
HALS medium

Solvent:
Aluminium hydroxide gel
HALS medium

6.2 Major incompatibilities

Do not mix with any other veterinary medicinal product, except solvent supplied for use with the veterinary medicinal product.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after reconstitution according to directions: use immediately.

6.4 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

6.5 Nature and composition of immediate packaging

Type I glass vial containing 5 or 25 doses (20 or 100 ml) of solvent, closed with chlorobutyl rubber stopper and sealed with aluminium cap.
Type I glass vial containing 5 or 25 doses of lyophilisate, closed with bromobutyl rubber stopper and sealed with aluminium cap.

Cardboard box with 1 glass vial of lyophilisate (5 doses) and 1 glass vial of solvent (20 ml).
Cardboard box with 1 glass vial of lyophilisate (25 doses) and 1 glass vial of solvent (100 ml).

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP

8. MARKETING AUTHORISATION NUMBER

Vm 42058/5144

9. DATE OF FIRST AUTHORISATION

02 February 2021

10. DATE OF REVISION OF THE TEXT

September 2024

PROHIBITION OF SALE, SUPPLY AND/OR USE
Not applicable.

11. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' or 'PID' on www.gov.uk.

Gavin Hall

Approved 01 October 2024